ETON Stock Analysis: Buy, Sell, or Hold?
ETON - Eton Pharmaceutcials, Inc. Common Stock
$63.47
3.56 (5.94%)
▲
5d:
+7.83%
30d:
+43.79%
90d:
+81.34%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When ETON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ETON is 27.9% above its trading range ($49.62). Market expects 12.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ETON is 27.9% above its trading range ($49.62). Market expects 12.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$87.92
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$54.59
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ETON is currently trading at $63.47, which is considered extended relative to its 30-day fair value range of $38.26 to $49.62. From a valuation perspective, the stock is trading at a premium (Forward PE: 24.6) compared to its historical average (17.5). At these levels, the market is pricing in 12.0% annual earnings growth.
Technical Outlook: Technically, ETON is in a strong uptrend. The price is approaching resistance at $64.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: ETON scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $71.00 (+11.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ETON is in a strong uptrend. The price is approaching resistance at $64.00. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.9% recently.
Market Sentiment: ETON scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $71.00 (+11.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$38.26 -
$49.62
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
24.8%
All Signals
- BEARISH: Price significantly overextended (+27.9% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.9%)
- BULLISH: Trading below Wall St target ($71.00)
- BULLISH: Expecting earnings turnaround to 12.0% growth with 98.6% revenue growth
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$38.26 -
$49.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$40.61
Resistance Level
$64.00
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.60
Wall Street Target
$71.00
(+11.9%)
Revenue Growth (YoY)
98.6%
Earnings Growth (YoY)
-12.6%
Profit Margin
12.0%
Valuation Premium vs History
+12.0% premium
PE vs Historical
24.6 vs 17.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+12.0%
(market-implied from PE analysis)
1-Year Target
$71.09
(+12%)
2-Year Target
$79.62
(+25%)
3-Year Target
$89.17
(+41%)
3-Yr Target (if PE normalizes)
(PE: 25→18)
PE COMPRESSION
$63.43
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 24.6, Growth: 84.3%)
$214.21
(+238%)
Base:
(SPY PE: 20.1, Growth: 84.3%)
$174.76
(+175%)
Bear:
(PE: 17.1, Growth: 84.3%)
$148.55
(+134%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (45x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Forward PE: 45.45 | Forward EPS (Implied): $1.40
Bull Case
$76.64
(+21%)
Analyst growth 15.0%, PE expands to 47.7
Base Case
$63.47
(0%)
Market implied 0.0%, PE stable at 45.5
Bear Case
$48.55
(-24%)
Severe decline -15.0%, PE contracts to 40.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 6:27 AM ET
Data refreshes hourly during market hours. Next update: 7:27 AM
Data refreshes hourly during market hours. Next update: 7:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ETON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$653 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
